(Total Views: 601)
Posted On: 08/08/2021 12:25:10 PM
Post# of 153905
It's not just that he specified leronlimab in the patent and was working for Cytodyn, it's that IncellDX applied for a patent for the use of any CCR5/CCL5 inhibitor to treat the covid cytokine storm.
The patent mentions leronlimab, maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779 and seemingly anything else that inhibits CCR5/CCL5. I'm guessing that this includes drugs that haven't been discovered yet and even herbs, there are some that show evidence of inhibiting CCR5.
This all seems ludicrous to me and the patent office agreed with that but there does seem to be a big grey area with the broad ability to patent treatments in the US so I understand why Patterson thought it was patentable, even though I think it's unethical to stake a claim to such a generalized potentially life-saving treatment.
Here is the patent application in question:
IncellDX patent application
The patent mentions leronlimab, maraviroc, vicriviroc, aplaviroc, SCH-C, TAK-779 and seemingly anything else that inhibits CCR5/CCL5. I'm guessing that this includes drugs that haven't been discovered yet and even herbs, there are some that show evidence of inhibiting CCR5.
This all seems ludicrous to me and the patent office agreed with that but there does seem to be a big grey area with the broad ability to patent treatments in the US so I understand why Patterson thought it was patentable, even though I think it's unethical to stake a claim to such a generalized potentially life-saving treatment.
Here is the patent application in question:
IncellDX patent application
(6)
(0)
